Lenvatinib enhances antitumor immunity by promoting the infiltration of TCF1 + CD8 + T cells in HCC via blocking VEGFR2
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Science"
DOI: 10.1111/cas.15719
Abstract: Lenvatinib is the favorable treatment for advanced hepatocellular carcinoma (HCC), and it is currently undergoing phase III clinical trials. However, the specific effects of lenvatinib on PD1+ CD8+ T cells in HCC microenvironment have not… read more here.
Keywords: lenvatinib; cells hcc; cd8 cells; treatment ... See more keywords